Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-13
2007-11-13
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S309000, C544S331000, C546S141000
Reexamination Certificate
active
10956006
ABSTRACT:
Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
REFERENCES:
patent: 2002/0077486 (2002-06-01), Scarborough et al.
patent: WO 99/05144 (1999-02-01), None
patent: WO 99/36425 (1999-07-01), None
patent: WO 01/57037 (2001-08-01), None
Yin, J. and S.L. Buchwald, “Palladium catalyzed intermolecular coupling of aryl halides and amides.”Org. Lett., vol. 2, pp. 1101-1104 (2000).
Berge, S.M., et al, “Pharmaceutical salts.”J. Pharmaceut. Sci., vol. 66, No. 1., pp. 1-19 (1977).
Fratantoni J.C. and B.J. Poindexter, “Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies.”Am. J. Clin. Pathol., vol. 94, No. 5; pp. 613-617 (1990).
Fredholm, B.B. et al., “Towards a revised nomenclature for P1 and P2 receptors.”Trends Pharmacol. Sci., vol. 18, No. 3; pp. 79-82 (1997).
Hechler, B. et al., “The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation.”Blood, vol. 92, No. 1; pp. 152-159 (1998).
Hollopeter, G. et. al., “Identification of the platelet ADP receptor targeted by antithrombotic drugs.”Nature, vol. 409, No. 6817; pp. 202-207 (2001).
Humphries et al., “A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis.”Trends Pharmacol. Sci., vol. 16, No. 6; pp. 179-181 (1995).
Ingall, A.H. et al., “Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.”J. Med. Chem., vol. 42, No. 2, pp. 213-220 (1999).
Jantzen, H.M. et al., “Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.”Thromb. Haemost., vol. 81, No. 1; pp. 111-117 (1999).
King, B.F. et al., “Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors.”Trends Pharmacol. Sci., vol. 19, No. 12; pp. 506-514 (1998).
Kunapuli, S.P. and J.L. Daniel, “P2 receptor subtypes in the cardiovascular system.”Biochem. J., vol. 336, No. 3; pp. 513-523 (1998).
Kunapuli, S.P., “Multiple P2 receptor subtypes on platelets: a new interpretation of their function.”Trends Pharmacol. Sci., vol. 19, No. 10; pp. 391-394 (1998).
Mills, D.C.B.. “ADP receptors on platelets.”Thromb. Haemost., vol. 76, No. 6, pp. 835-856 (1996).
Quinn, M.J. and D.J. Fitzgerald, “Ticlopidine and clopidogrel.”Circulation, vol. 100, No. 15; pp. 1667-1672 (1999).
Kane-MaGuire Kim A.
Marlowe Charles K.
Scarborough Robert M.
Smyth Mark S.
Zhang Xiaoming
Davis Zinna N.
Portola Pharmaceuticals Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Substituted isoquinolinones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted isoquinolinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted isoquinolinones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825703